Gilead’s Livdelzi®(Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA

  1. Home /
    2. PBC News /
  2. Gilead’s Livdelzi®(Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA
PBC News

Gilead’s Livdelzi®(Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA

The U.S. Food and Drug Administration (FDA) has granted accelerated approval for Livdelzi® (seladelpar) for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA. Learn more.